New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2013
08:46 EDTOWW, DGIT, APP, NQ, YUM, MRK, SINA, XRX, AVNR, LLY, JCPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: NQ Mobile (NQ), up 10%... Sina (SINA), up 6.5%. ALSO HIGHER: Digital Generation (DGIT), up 38% after selling television ad delivery business for $485M, announcing plan to form new company that will hold DG's online business... Avanir Pharmaceuticals (AVNR), up 9% after announcing an agreement to co-promote Merck (MRK) therapies in U.S. long-term care institutions... Eli Lilly (LLY), up 4.3% after lung cancer drug met endpoint in trial... Xerox (XRX), up 3% following upgrade to Buy from Neutral at Citigroup... J.C. Penney (JCP), up 1.4% after Bill Ackman resigns from board. DOWN AFTER EARNINGS: American Apparel (APP), down 4.5%. ALSO LOWER: Yum! Brands (YUM), down 3.2% after announcing July same-store sales in its China division fell 13%, including a 16% drop at KFC stores... Orbitz Worldwide (OWW), down 12% after announcing PAR Capital Management has sold 8.1M of its 24.6M shares of Orbitz Worldwide stock.
News For JCP;XRX;YUM;LLY;SINA;NQ;AVNR;MRK;APP;DGIT;OWW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 17, 2014
19:11 EDTXRXXerox management to meet with Piper Jaffray
Subscribe for More Information
16:04 EDTLLYEli Lilly says empagliflozin tablets reduced A1C, body weight and abdominal fat
Empagliflozin tablets reduced hemoglobin A1C (a measure of average blood sugar over the past two to three months), body weight and several markers of abdominal fat in adults with type 2 diabetes, according to a new retrospective analysis of clinical trial data presented on behalf of Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company at the 2014 Scientific Sessions of the American Heart Association in Chicago. Abdominal fat, also known as visceral fat, sits on or near vital organs. The study presented at AHA included analyses of two sets of adults with T2D treated with either empagliflozin or placebo. The first group consisted of 823 adults with high blood pressure who were treated for 12 weeks, while the second examined a pool of 2,476 adults from four different trials who were treated for 24 weeks. These randomized studies compared empagliflozin with placebo as an add-on to existing therapy, including metformin, metformin plus sulfonylurea, or pioglitazone with or without metformin. In both groups, treatment with empagliflozin significantly reduced A1C, body weight and several markers of abdominal fat compared with placebo. Changes in estimated total body fat did not reach statistical significance.
14:21 EDTJCPEarnings Preview: Home Depot shares up over 17% since last earnings report
Subscribe for More Information
12:03 EDTJCPOptions with decreasing implied volatility
Subscribe for More Information
11:55 EDTMRKMerck says IMPROVE-IT study met all primary, secondary endpoints
Merck announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN which combines simvastatin with the non-statin ZETIA -- experienced significantly fewer major cardiovascular events than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions. Merck plans to submit the data from IMPROVE-IT to the U.S. Food and Drug Administration in mid-2015 to support a new indication for reduction of major cardiovascular events for VYTORIN and ZETIA. VYTORIN and ZETIA are currently indicated for use along with a healthy diet to reduce elevated LDL cholesterol in patients with hyperlipidemia. The current U.S. Prescribing Information for both products states that the effect of ezetimibe on cardiovascular morbidity and mortality, alone or incremental to statin therapy, has not been determined.
11:06 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:34 EDTMRKMerck says IMPROVE-IT met primary endpoint
Subscribe for More Information
07:48 EDTSINAE-House provides additional capital for Shanghai Weidian
Subscribe for More Information
November 16, 2014
13:26 EDTMRKMerck: KEYTRUDA showed superiority to chemotherapy for primary endpoint of PFS
Subscribe for More Information
November 14, 2014
14:53 EDTLLY, MRKCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
13:39 EDTAPPBigger Capital calls for American Apparel's board to be reconstituted
Bigger Capital Fund and the Bigger Family, collectively owning more than 2M shares of American Apparel announced that they have delivered a letter to American Apparel's board. In the letter, Bigger Capital said, We write to you to express our serious and growing concerns with the company and provide the basis for our conviction that the board must be immediately reconstituted to replace David Danzinger and Allan Mayer with direct representatives of American Apparel's minority shareholders... We renew our call for the resignations of Messrs. Danzinger and Mayer for a number of reasons... we are becoming increasingly concerned that the new Board, led by Co-Chairmen Danzinger and Mayer, is not as committed to protect the interests of all shareholders as we had hoped. For example, this Board never bothered to respond to our July 17th letter or address our concerns in any form. At a time when the Company is suffering ever widening losses, is embroiled in a much publicized investigation of its former CEO, is still absorbing changes in its senior executive team, and the stock is taking a beating, the Board has a heightened responsibility to soothe shareholder concerns and assure us that all is being done to protect our investment. Such disregard of minority shareholders especially at this critical time is inexcusable... As things currently stand, American Apparel is continuing to sustain massive losses and erosion of shareholder value persists. The Company has massively underperformed peers on a profitability basis for years... Our expectation is that the Board will immediately engage with us to work constructively towards a solution along the lines laid out in this letter."
11:46 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
10:00 EDTSINAOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:25 EDTSINASINA downgraded to Equal Weight from Overweight at Barclays
Subscribe for More Information
09:16 EDTSINAOn The Fly: Pre-market Movers
Subscribe for More Information
08:04 EDTSINASINA price target lowered to $60 from $70 at Piper Jaffray
Subscribe for More Information
07:58 EDTSINASINA downgraded at Stifel
As noted earlier, Stifel downgraded SINA to Hold from Buy and removed the stock from its Select List. The firm downgraded the stock based on a lack of positive catalysts.
07:20 EDTSINASINA downgraded to Hold from Buy at Stifel
Subscribe for More Information
07:15 EDTSINASINA price target lowered to $58 from $67 at Brean Capital
Subscribe for More Information
06:22 EDTSINAStocks with implied volatility above IV index mean; SPLS SINA
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use